medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2011, Number 2

<< Back Next >>

Alerg Asma Inmunol Pediatr 2011; 20 (2)

Comparison between the use of ciclesonide versus fluticasone in the treatment of asthma in children

Arablin OSE, Huerta LJG, Olmo H

Language: Spanish
References: 29
Page: 65-76
PDF size: 136.80 Kb.


ABSTRACT

Background: The maintenance treatment in pediatric patients with asthma is based in the use of aerosol corticosteroids, where we have ciclesonide and fluticasone. There are two types of inhalation dispensers for their use: in one side the measured dosage inhalator (MDI) and on the other side dry powder inhalator (DPI). Objective: To compare the utility between ciclesonide versus fluticasone, and the difference using them with MDI or DPI for treatment of asthma in children. Search strategy: A search was done in journals databases as PUBMED, EMBASE, LILACS and Cochrane library. Selection criteria: We searched for studies comparing treatment with ciclesonide versus fluticasone, both in DMI and DPI, in the treatment of children younger than 18 years diagnosed with asthma. Results: As well as fluticasone, ciclesonide showed same amelioration of disease control parameters, and also in patient’s quality of life. Referring to adverse events, ciclesonide showed the advantage of not inhibiting cortisol secretion. Conclusions: Ciclesonide is equally effective as fluticasone in the treatment of children with persistent moderate and severe asthma. Besides, bioavailability of ciclesonide allows administration once a day with fewer adverse events.


REFERENCES

  1. Asthma Fact Sheet No. 7. World Health Organization. www.who.com 2008.

  2. Global initiative for asthma. Global strategy for asthma management and prevention. National Heart, Lung and Blood Institute/World Health Organization workshop report. 2008.

  3. Global strategy for the diagnosis and management of asthma in children 5 years and younger. National heart, lung and blood institute/world health organization workshop report. 2009.

  4. Sierna-Monge JJ, Del Río BE et al. Asma en el niño. En: Méndez JI, Huerta JG et al. Alergia: Enfermedad multisistémica. Editorial Médica Panamericana, 2008: 135-152.

  5. Mussaffi H, Omer R, Prais D et al. Computerized paediatric asthma quality of life questionnaires in routine care. Arch Dis Child 2007; 92: 678-682.

  6. Ricciardolo FL. The treatment of asthma in children: Inhaled corticosteroids. Pulmonary Pharmacology & Therapeutics 2007; 20: 473–482.

  7. Abdullah AK, Khan S. Evidence-based selection of inhaled corticosteroid for treatment of chronic asthma. Journal of Asthma 2007; 44: 1-12.

  8. Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults (Review). Cochrane Database Syst Rev 2008; 16 (2): CD 007031.

  9. Gulliver T, Morton R, Eid N. Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy an other clinical considerations. Paediatr Drugs 2007; 9(3): 185-94.

  10. Rizzo MC, Solé DJ. Inhaled corticosteroids in the treatment of respiratory allergy: safety versus efficacy. J Pediatr Rio J 2006; 82(5): S198-205.

  11. Pedersen S, Engelstäter R et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology & Therapeutics 2009; 22: 214-220.

  12. Gelfand EW, Georgitis JW, Noonan M, Ruff ME. Once daily ciclesonide in children: Efficacy and safety in asthma. The Journal of Pediatrics 2006: 377-384.

  13. Urbano FL. Review of the NAEPP 2007 expert panel report on asthma diagnosis and treatment guidelines. J Manag Care Pharm 2008; 14(1): 41-49.

  14. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy 2004; 59(5): 469-78.

  15. Martínez-Vázquez MA, Torres-Medina M. Asma y estado de mal asmático. Epidemiología 2004; 21(30): 1-3.

  16. Aguilar RJM, León BV, Baeza BMA. Prevalencia de asma aguda en niños y adolescentes de Mérida, Yucatán, México. Revista Alergia México 2009; 56(1): 3-8.

  17. Sanín-Aguirre LH, Téllez-Rojo, Martha M. LaCasaña-Navarro M. Prevalencia de asma y otras enfermedades alérgicas en niños escolares de Ciudad Juárez, Chihuahua Albino Barraza-Villarreal. Salud Pública de México 2001; 43(5): 433-443.

  18. Tatto-Cano MI, Sanín-Aguirre LH, González V, Ruiz-Velasco S, Romieu I. Prevalencia del asma, rinitis y eczema en niños escolares de Cuernavaca, Morelos. Salud Pública Mex 1997; 39(6): 497-506.

  19. Illi S, von ME, Lau S, Niggemann B, Gruber C, Wahn U. Perennial allergen sensitization early in life and chronic asthma in children: a birth cohort study. Lancet 2006; 368: 763–770.

  20. Busse WW, Rosenwasser LJ. Mechanisms of asthma. J Allergy Clin Immunol 2003; 111(3, Part 2): S799.

  21. Sandford AJ, Chagani T, Zhu S et al. Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity. J Allergy Clin Immunol 2000; 106(1 Pt 1): 135-4023.

  22. Minshall EM, Leung DYM, Martin RJ et al. Eosinophil associated TGF‚ 1 mRNA expression and airways fibrosis in asthma. Am J Respir Cell Mol Biol 1997; 17: 326-33.

  23. Anderson HR, Pottier AC, Strachan DP. Asthma from birth to age 23: incidence and relation to prior and concurrent atopic disease. Thorax 1992; 47: 537–542.

  24. Barbee RA, Murphy S. The natural history of asthma. J Allergy Clin Immunol 1998; 102(4, Part. 2): S65.

  25. Tonnel AB, Tillie-Leblond I. IqE dependent hypersensitivity and allergic inflammation. Rev Prat 2007; 57: 1306-12.

  26. Holgate ST. The cellular and mediator basis of asthma in relation to natural history. Lancet 1997; 350(Suppl. 2): SII5.

  27. Magnan A, Vervloet D. Pathophysiological mechanisms of asthma and atopy: old and new concepts. Bull Acad Natl Med 2005; 189: 1451-9.

  28. Gomes I, Mathur SK, Espenshade BM et al. Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: Implications in fibrogenesis. J Allergy Clin Immunol 2005; 116: 796-804.

  29. Chiappara G, Gagliardo R, Siena A. et al. Airway remodelling in the pathogenesis of asthma. Curr Opin Allergy Clin Immunol Review 2001; 1: 85-93.




2020     |     www.medigraphic.com